deadline by which license applications must be received.

SUPPLEMENTARY INFORMATION:

The National Institute of Environmental Health Sciences has developed procedures and a prototype device for isolation of proteins from complex mixtures for protein sequencing. The system serves as a one-step purification method for isolation of biologically relevant proteins affected by disease or experimental treatment and has been described in Electrophoresis 15,535–545,1994. The system includes a preparative isoelectric focusing device for separation of proteins by charge, a glass mold for preparative polyacrylamide gel separation by mass and a protocol for use.

The commercial advantage of the Preparative Two Dimensional Gel Electrophoresis system is to separate and isolate sufficient amounts of individual protein for sequencing in a powerful one-step purification method. The Preparative Two Dimensional Gel Electrophoresis system can resolve individual proteins by charge and mass from up to 1 to 2 mg of unpurified starting material from protein mixtures. Current devices for two dimensional gel electrophoresis are generally for analytical scale work and are not physically or procedurally adapted to accommodate preparative sample loads. Although other preparative electrophoresis devices do exist, they separate by either mass or charge alone and function as stand-alone units without ready integration into additional systems for resolution of individual proteins.

The developed technology has applications for protein sequencing, protein immunization for antibody production, immunostaining and other modes of protein characterization. Although the system has been tested and is operational, some refinements in protein resolution are still possible which may involve procedural, reagent or equipment modifications.

The CRADA awardees will have an option to negotiate for an exclusive license to market and commercialize any new technology developed within the scope of the CRADA research plan for the Preparative Two Dimensional Gel Electrophoresis System. This CRADA may be directed toward the co-development of improved preparative electrophoresis equipment and pertinent procedures.

Roles of NIEHS

1. Provide design and specifications of an operating prototype device, provide a protocol for prototype operation, provide user expertise, and assist in beta testing.

2. Work cooperatively with the company(s) to determine the market potential for the Preparative Two Dimensional Gel Electrophoresis system and to refine the prototype system.

Roles of the CRADA Partner

1. Provide expertise in application and commercial-oriented separation systems.

2. Develop plan for production, testing and commercialization of Preparative Two Dimensional Gel Electrophoresis system.

Selection criteria for choosing the CRADA partner(s) will include, but will not be limited to the following:

1. Experience in manufacturing electrophoresis devices or related separation technologies.

2. Capability to develop, implement and manage the product commercialization so as to ensure the dissemination of the technology(s) to research or health care services.

3. Ability to cost share for production and testing of a preparative two-dimensional gel electrophoresis device.

Dated: March 13, 1995.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 95–6854 Filed 3–20–95; 8:45 am]

BILLING CODE 4140–01–P

National Heart, Lung, and Blood Institute; Meeting

Pursuant to Pub. L. 92–463, notice is hereby given of the meeting of the following Heart, Lung, and Blood Special Emphasis Panel.

The meeting will be open to the public to provide concept review of proposed contract or grant solicitations.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should inform the Contact Person listed below in advance of the meeting.

Name of Panel: NHLBI SEP on Blood Diseases.

Dates of Meeting: April 27–28, 1995.

Time of Meeting: 9 a.m.

Place of Meeting: National Institutes of Health, Natcher Building, Building 45, Lower Level Room D, Bethesda, Maryland.

Agenda: The panel will review the current status of research in the designated areas, identify gaps and make recommendations regarding opportunities and priorities for future contract or grant solicitations.

Contact Person: Dr. Fann Harding, 7550 Wisconsin Avenue, Room 5A08, Bethesda, Maryland 20892, (301) 496–1817.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health)

Dated: March 14, 1995.

Margery G. Grubb,

Senior Committee Management Specialist, National Institutes of Health.

[FR Doc. 95–6851 Filed 3–20–95; 8:45 am]

BILLING CODE 4140–01–M

National Heart, Lung, and Blood Institute; Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Heart, Lung, and Blood Special Emphasis Panel (SEP) meetings:

Name of SEP: Response and Adaptation to Exercise-Unit II (Telephone Conference Call).

Date: April 6, 1995.

Time: 1 p.m.

Place: 5333 Westbard Avenue, Room 552, Bethesda, Maryland.

Contact Person: S. Charles Selden, Ph.D., 5333 Westbard Avenue, Room 552, Bethesda, Maryland 20892, (301) 594–7476.

Purpose/Agenda: To review and evaluate grant applications.

Name of SEP: The Insulin in Resistance Atherosclerosis Study (IRAS).

Date: April 18, 1995.

Time: 12:30 p.m.

Place: Crystal Gateway Marriott, Arlington, Virginia.

Contact Person: David Monsees, Jr., Ph.D., 5333 Westbard Avenue, Room 550, Bethesda, Maryland 20892, (301) 594–7450.

Purpose/Agenda: To review and evaluate grant applications.

These meetings will be closed in accordance with the provisions set forth in sec. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health)

Dated: March 14, 1995.

Margery G. Grubb,

Senior Committee Management Specialist, National Institutes of Health.

[FR Doc. 95–6850 Filed 3–20–95; 8:45 am]

BILLING CODE 4140–01–M